Provided herein is a coated coronary stent, comprising: a. stent framework; b. a plurality of layers deposited on said stent framework to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.

Medical devices and methods for drying medical devices are disclosed. An example method for drying a medical device may include disposing a medical device within a drying apparatus. The drying apparatus may include a variable frequency microwave heating device. The medical device may include a substrate, the substrate including an active pharmaceutical ingredient and a solvent. The method may also include heating the medical device with the drying apparatus. Heating may evaporate at least a portion of the solvent.

The present application relates to the field of pharmaceutical technology, in particular, to a drug-loaded medical device, including a medical device body and at least one drug coating, the drug coating is attached to at least one side of a surface of the medical device body. The main component of the drug coating includes a macrolide drug. The drug coating includes elongated prismatic crystals each with at least three lateral edges, and/or the drug coating includes crystal clusters of the elongated prismatic crystals each with at least three lateral edges. An aspect ratio of each elongated prismatic crystal is in a range from 1:1 to 40:1.

A method of treating peripheral artery diseases in lower limbs by providing a medical device having an expandable member having a drug coating layer which has a crystalline morphological form including a plurality of crystal particles of a water-insoluble drug regularly arranged and uniformly sized on the surface of the medical device, inserting the medical device in peripheral blood vessels, expanding the expandable member, pressing the drug coating layer to a blood vessel wall such that at least part of the plurality of crystals are transferred to the blood vessel wall, and deflating the expandable member such that a pharmacokinetics profile is presented in which a drug concentration in the blood vessels is kept for the inhibition of smooth muscle cell proliferation in a high drug-concentration period of time, and for the non-inhibition of endothelial cell growth in a later low drug-concentration period of time.

A balloon catheter is disclosed having a balloon at a distal portion of a catheter shaft and on a surface of the balloon with elongate bodies which are crystals of a water-insoluble drug having independent long axes. The balloon in a deflated state has a plurality of wing portions in a circumferential direction, and a circumferential surface portion along a circumferential direction of the catheter shaft, the wing portions being folded along the circumferential direction of the balloon. Surface of the circumferential surface portion which faces the folded wing portion has a region in which tip portions are not in contact with the surface of the balloon or with other elongate bodies, and surface face of the folded wing portion which faces an outer circumferential side has a region in which the tip portions are in contact with the surface of the balloon or with other elongate bodies.

Medical devices and methods for drying medical devices are disclosed. An example method for drying a medical device may include disposing a medical device within a drying apparatus. The drying apparatus may include a variable frequency microwave heating device. The medical device may include a substrate, the substrate including an active pharmaceutical ingredient and a solvent. The method may also include heating the medical device with the drying apparatus. Heating may evaporate at least a portion of the solvent.

The present invention relates to a drug-eluting medical device, in particular a balloon for angioplasty catheters with drug elution to prevent the restenosis of the vessel subjected to angioplasty. More particularly, the present invention relates to a catheter balloon completely or partially coated with paclitaxel in hydrated crystalline form or in hydrated solvated crystalline form, having an immediate release and bioavailability of a therapeutically effective amount of paclitaxel at the site of intervention. The balloon can be made of a polyether-polyamide block copolymer, or a polyester amide, or polyamide-12.

A balloon catheter is disclosed that can effectively deliver a drug to living body tissue, a method of manufacturing a balloon catheter, and a treatment method. A balloon catheter is disclosed, the balloon catheter is provided on an outer surface of a balloon with a plurality of elongate bodies which are independent crystals of a water-insoluble drug extending in an elongate form. The elongate bodies include fixed-side elongate bodies which are fixed to the outer surface side of the balloon, and top-side elongate bodies which are bent or broken from the fixed-side elongate bodies and are continuous with or independent of the fixed-side elongate bodies.

A balloon catheter is disclosed capable of effectively delivering a drug to living body tissue and a manufacturing method of the balloon catheter, and a treatment method. The balloon catheter has a balloon at a distal portion of a catheter shaft, and is provided on a surface of the balloon with elongate bodies which are crystals of a water-insoluble drug extending in a longitudinal direction. The surface of the balloon is provided with crystal conjugates formed of a plurality of elongate bodies united to one another while being in a tilted state.

A balloon catheter by which a drug can be effectively delivered to living body tissue and a method of manufacturing the balloon catheter, and a treatment method. The balloon catheter is provided on an outer surface of a balloon with a plurality of elongate bodies which are independent crystals of a water-insoluble drug that extend in an elongate form. The elongate bodies have long axes extending in directions along the outer surface of the balloon when the balloon is in a deflated state. Deformation, when the balloon is inflated from the deflated state, of portions on an outer surface side of the balloon to which end portions of the elongate bodies are fixed causes a force to act on the elongate bodies such that the long axes of the elongate bodies approach perpendicularity to the outer surface of the balloon.